KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into...
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for...
Market Outlook Biomarker-driven prescribing continues to play an increasingly prominent role in key oncology indications. Biomarkers play an...
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for...
The treatment landscape for colorectal cancer is based on chemotherapies and targeted agents, although the latter (e.g., Avastin, Erbitux, Vectibix...
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to...
Market Outlook The treatment paradigm for second- and subsequent-line advanced or metastatic colorectal cancer revolves around targeted agents (...
DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide...
Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA), Vectibix (Amgen), Zaltrap (Regeneron/Sanofi), Cyramza (Eli Lilly), Stivarga...
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide....
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide....
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide....
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide....
DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide....
Introduction Colorectal cancer (CRC) affects several thousands of people in Brazil and Mexico. Once it metastasizes, the only available...
Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza—are approved in the United...
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year OS of Current treatment for metastatic colorectal cancer...
Several therapies are available for treatment of second- and subsequent-line advanced/ metastatic colorectal cancer that have a positive effect of...
Get content updates to your inbox
Subscribe